Author

Kanut Laoharawee

University of MinnesotaORCID 0000-0001-8216-2131Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Assay:CRISPR screen· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Research Focus:differential expression· 1

Frequent Co-Authors

Beau R. WebberiD· 3 shared Branden S. MoriarityiD· 3 shared Nicholas J. SlipekiD· 2 shared Walker S. LahriD· 2 shared Alexandria K. Gilkey· 1 shared Bryce J. WickiD· 1 shared Ella J. EatoniD· 1 shared Emily J. PomeroyiD· 1 shared

Activity by Year

2018-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

Beau R. WebberORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BioengineeringJournal for ImmunoTherapy of CancerPeer-reviewedMay 1, 2025

Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing

Minjing Wang, Joshua B. Krueger, Alexandria K. Gilkey…·Branden S. Moriarity

This study enhances CAR-NK cell functionality using non-viral base editing and transposon integration, showing improved therapeutic potential in Burkitt's lymphoma models.

48 citationstop 1%

humanCRISPR screen

𝕏 PostBluesky

BioengineeringMolecular TherapyPeer-reviewedOct 4, 2024

Engineering Memory T Cells as a platform for Long-Term Enzyme Replacement Therapy in Lysosomal Storage Disorders

Evan W. Kleinboehl, Kanut Laoharawee, Jacob D. Jensen…·Branden S. Moriarity

This study demonstrates that genetically engineered memory T cells can deliver enzyme replacement therapy for mucopolysaccharidosis type I, reducing GAG levels in multiple tissues for up to 22 weeks.

3 citations

mouseproteomics

𝕏 PostBluesky

GenomicsScientific ReportsPeer-reviewedAug 8, 2018

Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease

Matthew J. Johnson, Kanut Laoharawee, Walker S. Lahr…·Branden S. Moriarity

This paper describes optimized CRISPR/Cas9 genome engineering of primary human B cells, achieving high-efficiency gene knockout and site-specific integration.

81 citations

humanCRISPR screen

𝕏 PostBluesky